KMUi-Biomedizin-1: Entwicklung und präklinische Qualifizierung neuartiger Parodontitis-Therapeutika für die klinische Anwendung (ParoPaste) - Erforschung und präklinische Qualifizierung neuartiger Parodontitis-Therapeutika in Proof-of-Concept Modellen und regulatorische Vorbereitung für die klinische Anwendung

Alternative metal binding groups in drugs for the treatment of periodontitis - AMePA

Controlled release drug delivery systems of innovative and selective drug molecules for the treatment of bacterial infectious diseases of the periodontum – ParoStop

Profiling inhibitors of bacterial glutaminyl cyclases as drug prototypes of novel periodontal therapeutics - PInParo

Clinical validation of the demonstrator toothpaste and expansion into animal health - GingiTrap
Preparation of a long-acting antibiotic for Phase 1 trials in severe periodontitis - MinoPro

Further development and commercialization of innovative product lines based on a novel active ingredient targeting periodontitis-associated bacteria, with potential for additional applications.